CytomX Therapeutics (CTMX)
(Delayed Data from NSDQ)
$1.17 USD
-0.02 (-1.68%)
Updated Sep 19, 2024 04:00 PM ET
After-Market: $1.17 0.00 (0.00%) 7:52 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
CTMX 1.17 -0.02(-1.68%)
Will CTMX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CTMX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CTMX
CytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains?
Vanda (VNDA) to Report Q1 Earnings: What's in the Cards?
CTMX: What are Zacks experts saying now?
Zacks Private Portfolio Services
GSK Gears Up for Q1 Earnings: Here's What to Expect
Incyte (INCY) to Report Q1 Earnings: What's in the Cards?
AbbVie (ABBV) to Report Q1 Earnings: What's in the Cards?
Other News for CTMX
CytomX Therapeutics Announces First Patient Dosed with CX-801, a Dually-Masked Interferon-Alpha 2b PROBODY?, in a Phase 1 Study in Patients with Solid Tumors
CytomX Therapeutics to Present at Upcoming September Investor Conferences
CytomX Therapeutics, Inc. (CTMX) Q2 2024 Earnings Call Transcript
CytomX Therapeutics (CTMX) Gets a Buy from Wedbush
CytomX Therapeutics files $250M mixed securities shelf